Formulations for controlled release of bupivacaine

Patent metadata

Field	Value
Publication number	US-10292909-B2
Application number	US-201815918026-A
Country	US
Kind code	B2
Filing date	Mar 12, 2018
Priority date	May 9, 2017
Publication date	May 21, 2019
Grant date	May 21, 2019

Abstract

The disclosure provides biocompatible dental material that is moldable and biodegradable and provides sustained and/or controlled delivery of one or more local anesthetics within a dental cavity or space. Such dental material is customizable for the size and shape needed for a particular patient or particular application. The dental material may also provide customizable sustained and/or controlled delivery of one or more local anesthetics.

First claim

What is claimed is:

1. A biocompatible dental putty comprising a biodegradable hemostatic matrix having biodegradable microparticles dispersed therein, said biodegradable microparticles encapsulating a local anesthetic agent, wherein the biodegradable microparticles upon biodegradation thereof release the local anesthetic agent into the biodegradable hemostatic matrix and wherein the biodegradable hemostatic matrix is permeable to diffusion therethrough of the released local anesthetic agent, wherein the biodegradable microparticles have a loading of the local anesthetic of from 5% to 25% by weight, based on biodegradable microparticle weight, and wherein the biocompatible dental putty provides a biphasic release of the local anesthetic agent.

2. The biocompatible dental putty of claim 1 , wherein the biphasic release comprises release of from 13% to 28% of the local anesthetic agent after 24 hours, and release of from 66% to 88% of the local anesthetic agent after 5 days.

3. The biocompatible dental putty of claim 1 , as configured to completely degrade and be bioabsorbed in less than 7 days.

4. The biocompatible dental putty of claim 1 , wherein the biodegradable microparticles have diameters in a range of from 1 to 20 μm.

5. The biocompatible dental putty of claim 1 , wherein the biodegradable hemostatic matrix comprises a gelatin, collagen, or cellulose material.

6. The biocompatible dental putty of claim 1 , wherein the biodegradable hemostatic matrix comprises a gelatin material.

7. The biocompatible dental putty of claim 6 , wherein the gelatin material comprises a bovine gelatin material.

8. The biocompatible dental putty of claim 6 , wherein the gelatin material comprises a porcine gelatin material.

9. The biocompatible dental putty of claim 1 , wherein the biodegradable hemostatic matrix comprises a collagen material.

10. The biocompatible dental putty of claim 9 , wherein the collagen material comprises a microfibrillar collagen material.

11. The biocompatible dental putty of claim 9 , wherein the collagen material comprises a bovine collagen.

12. The biocompatible dental putty of claim 1 , wherein the biodegradable hemostatic matrix comprises a cellulose material.

13. The biocompatible dental putty of claim 12 , wherein the cellulose material comprises an oxidized regenerated cellulose material.

14. The biocompatible dental putty of claim 1 , wherein the biodegradable microparticles encapsulating the local anesthetic agent are present in an amount of from 33% to 66% by weight, based on total weight of the biodegradable hemostatic matrix and the microparticles encapsulating the local anesthetic agent.

15. The biocompatible dental putty of claim 1 , further comprising at least one ingredient selected from the group consisting of antibiotics, antifungals, anti-infectives, agents for prolonging duration of local anesthesia from the local anesthetic agent, agents that enhance the effectiveness of the local anesthetic agent, glucocorticoid agents, alkalinizing agents, non-glucocorticoid steroids, modulators of ionic transport across cell membranes, antipyretic agents, adrenergic receptor agonists, adrenergic receptor antagonists, tubulin binding agents, osmotic polysaccharides, potassium ATP channel agonists, potassium ATP channel antagonists, sodium, K-ATPase inhibitors and enhancers, neurokinin antagonists, phosphatidylinositol-specific phospholipase C inhibitors, inhibitors of leukocyte glucose metabolism, anticonvulsants, analeptic agents, tranquilizing agents, antidepressants, anti-seizure agents, leukotriene agonists and inhibitors, prostaglandin agonists and inhibitors, phosphodiesterase agonists and inhibitors, vasoconstrictor agents, and sympathomimetic agents.

16. The biocompatible dental putty of claim 1 , further comprising at least one ingredient selected from the group consisting of sulfisoxazole, penicillin, ampicillin, cephalosporins, amikacin, gentamicin, tetracyclines, chloramphenicol, erythromycin, clindamycin, isoniazid, rifampin, and derivatives and salts of the foregoing, amphotericin B, nystatin, ketoconazole, acyclovir, amantadine, chlorahexidine, epinephrine, norepinephrine, dopamine, metaraminol, phenylephrine, methoxamine, mephentermine, methysergide, ergotamine, ergotoxine, dihydroergotamine, sumatriptan, clonidine, guanfacine, guanabenz, dihydroxyphenylalanine, methyldopa, ephedrine, amphetamine, methamphetamine, methylphenidate, ethylnorepinephrine ritalin, and pemoline.

17. The biocompatible dental putty of claim 1 , wherein the biodegradable microparticles comprise polymeric material selected from the group consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polycaprolactone, polyesters, polyorthoesters, proteins, polysaccharides, and combinations of two or more of the foregoing.

18. The biocompatible dental putty of claim 1 , wherein the biodegradable microparticles comprise poly(lactic-co-glycolic acid) (PLGA).

19. The biocompatible dental putty of claim 18 , wherein the PLGA has a molecular weight of from 7 to 17 kDa.

20. The biocompatible dental putty of claim 1 , wherein the local anesthetic is selected from the group consisting of bupivacaine, mepivacaine, articaine, ropivacaine, dibucaine, etidocaine, tetracaine, lidocaine, prilocaine, and mixtures, salts, and derivatives of the foregoing.

21. The biocompatible dental putty of claim 1 , wherein the local anesthetic comprises bupivacaine.

22. The biocompatible dental putty of claim 1 , wherein the local anesthetic comprises a bupivacaine salt.

23. The biocompatible dental putty of claim 1 , wherein the local anesthetic comprises (S)-(−) bupivacaine.

24. A biocompatible dental putty comprising a biodegradable gelatin hemostatic matrix having biodegradable poly-(lactic-co-glycolic) acid microparticles dispersed therein, said biodegradable poly-(lactic-co-glycolic) acid microparticles encapsulating a local anesthetic agent comprising bupivacaine or a basic form, salt, or enantiomer thereof, wherein the biodegradable microparticles upon biodegradation thereof release the local anesthetic agent into the biodegradable hemostatic matrix and wherein the biodegradable hemostatic matrix is permeable to diffusion therethrough of the released local anesthetic agent, wherein the biodegradable microparticles have a loading of the local anesthetic of from 5% to 25% by weight, based on biodegradable microparticle weight, and wherein the biocompatible dental putty provides a biphasic release of the local anesthetic agent.

25. The biocompatible dental putty of claim 24 , as configured to completely degrade and be bioabsorbed in less than 7 days.

26. The biocompatible dental putty of claim 24 , wherein the biodegradable microparticles have diameters in a range of from 1 to 20 μm.

27. The biocompatible dental putty of claim 24 , wherein the biodegradable microparticles encapsulating the local anesthetic agent are present in an amount of from 33% to 66% by weight, based on total weight of the biodegradable hemostatic matrix and the microparticles encapsulating the local anesthetic agent.

Assignees

• Res Triangle Inst
• Univ North Carolina Chapel Hill

Inventors

• Johnson Leah Marie
• Rothrock Ginger Denison
• Shepherd Sarah Dorothy
• O'Buckley Sandra Cordel
• Neely Andrea Gail

Classifications

• A61K9/006 Primary

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K6/15

  Compositions characterised by their physical properties · CPC title

• A61K6/69 Primary

  Medicaments · CPC title

• A61K9/5026

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title